natgillin/translations-raw huggingface dataset:
Also preferred is an extended release tablet formulation, wherein the anionic polymer is a crosslinked acrylic acid polymer and wherein the content of the optionally crosslinked acrylic acid polymer in the matrix is from about 0.25 wt.-% to about 25 wt.-%, and preferably from about 0.5 wt.-% to about 15 wt.-%, and preferably from about 1 wt.-% to about 10 wt.-%. 
Formulacija tablete produljenog oslobađanja u skladu sa zahtjevom 2, naznačena time, da anionski polimer je po želji umreženi polimer akrilne kiseline, te pri čemu sadržaj po želji umreženog polimera akrilne kiseline u matrici je od oko 0.25 mas. % do oko 25 mas. %, te je povoljnije od oko 0.5 mas. % do oko 15 mas. %, te je najpovoljnije od oko 1 mas. % do oko 10 mas. %.
The package according to any one of claims 21-24, wherein said composition further comprises one or more species of lactobacilli selected from the group consisting of Lactobacillus salivarius subs. 
Pakiranje u skladu s bilo kojim od patentnih zahtjeva 21-24, naznačeno time što navedeni pripravak dodatno sadrži jednu ili više vrsta laktobacila koje se bira iz skupine koju čine Lactobacillus salivarius subsp.
A counter as claimed in claim 8 wherein said protrusions are equally spaced apart. 
Brojač kao što je zahtijevano u patentnom zahtjevu 5, gdje su navedena ispupčenja (705, 1516) drugih sredstava za angažiranje podjednako razmaknuta.
instructions executable by the processor to adjust the temporal envelope information by adjusting the each QMF subband sample to generate adjusted temporal envelope information using the predetermined parameter; and 
generator dodatnih informacije o vremenskoj ovojnici za analiziranje struje bitove kako bi se generiralo parametar za podešavanje informacija o vremenskoj ovojnici;
A process as claimed in claim 5 in which the heated liquid is delivered to the radiator element located inside the poultry shed. 
Postupak sukladno Zahtjevu 5 koji sadrži korak isporuke zagrijane tekućine u element za zagrijavanje (15) koji se nalazi unutar prostora za uzgoj gljiva (3).
R6-NCO (IV) wherein R6 represents C1-4 alkyl group, phenyl or optionally substituted phenyl group with an amine of formula (III): wherein R1 represents hydrogen atom or C1-4 alkyl group, R2 represents hydrogen atom or C1-4 alkyl group, and, where appropriate, separating the enantiomers and/or diastereomers, and/or cis- and/or trans-isomers of compounds of formula (I), or intermediates thereto, by conventional methods, and optionally thereafter forming salts and/or hydrates and/or solvates of the compound of formula (I). 
H, LI N pri čemu R' predstavlja vodikov atom ili C;.g alkil skupinu, R? predstavlja vodikov atom ili C,., alkil skupinu, i, gdje je prikladno, odvajanje enantiomera i/ili dijastereomera, i/ili cis- i/ili trans-izomera spojeva formule (1), ili njihovih intermedijera, konvencionalnim postupcima, te nakon toga, opcijski, oblikovanje soli i/ili hidrata i/ili solvata spoja formule (1).
Therefore, in a preferred embodiment, the functional derivative comprises at least one moiety attached to one or more functional groups, which occur as one or more side chains on the amino acid residues. 
Stoga, u poželjnoj izvedbi, funkcionalni derivati obuhvaćaju najmanje jedan ostatak vezan za jednu ili više funkcionalnih skupina koje se pojavljuju najednom ili više bočnih lanaca aminokiselinskih ostataka.
The blood pressure analyzer according to claim 12, wherein the input port is further configured to receive an electrocardiogram (ECG) signal corresponding to the PCG signal, and wherein the diastolic signal extractor is configured to extract the diastolic signal using the corresponding ECG signal. 
Uređaj za analizu krvnog tlaka prema zahtjevu 12, naznačen time da je ulazni priključak nadalje podešen za primanje signala elektrokardiograma (EKG) koji odgovara signalu PCG, te pri čemu je uređaj za izdvajanje dijastoličkog signala podešen za izdvajanje dijastoličkog signala korištenjem odgovarajućeg EKG signala,
The pharmaceutical composition of claim 11 or 12 for use in combination with anti-influenza therapy or in combination with a haemagglutinin containing influenza vaccine by contemporaneous or separate administration. 
Farmaceutski sastav prema zahtjevu 9 ili 10 za uporabu u skladu sa zahtjevom 9 ili 10, naznačen time, da se primjenjuje u kombinaciji sa cjepivom protiv gripe koje sadrži hemaglutinin, istodobnom ili odvojenom primjenom.
400-820 g/l dodine particles, and expressed by weight based on the total weight of the composition: 
Sastav koncentrata otopine sadrži, izraženo masom na temelju ukupne mase sastava:
Alternatively, as is shown in the FIGS. 4 a and 4 b, the connection sleeve 8 may instead comprise external threads for interaction with the expansion means 10 and suspension element 16, respectively. 
Alternativno, kako je prikazano na Slikama đa 1 4b, vezni rukavac 8 može umjesto toga imati vanjski narez za međudjelovanje s ekspanzionim sredstvom 10, odnosno ovjesnim elementom 16.
The present invention relates to a process and relevant system for manufacturing metal strips and sheets without discontinuity from the continuous casting of the melt until the last rolling stand, in particular for steel flat products, without any provision of intermediate products. BACKGROUND 
Predstavljeni izum se odnosi na postupak i odgovarajući sustav za proizvodnju metalnih ploča (limova) i traka bez prekida kontinuiranosti između kontinuiranog lijevanja taline sve do zadnjeg valjačkog stana, posebno za čelične plosnate proizvode, bez stvaranja međuproizvoda.
The method of claim 18, wherein said other drug is selected from the group consisting of Lactulose, lactitol, neomycin, metronidazole, rifaximin, and a combination of L-ornithine and L-aspartate. 
Pripravak za uporabu u skladu sa patentnim zahtjevom 17, naznačen time što je navedeni drugi lijek odabran iz skupine koja sadrži Laktulozu, laktitol, neomicin, metronidazol, rifaksimin, i kombinaciju L-ornitina i L-aspartata (LOLA).
In still further embodiments, such articles may also have one or more of the other properties listed above. In another embodiment, the polyurethane elastomer article has a Texus Flex value at 30% of greater than 10,000 cycles in accordance with ASTM procedure D-3629-99; and a tear strength of from 150 to 450 pli in accordance with ASTM procedure D-1938. 
Proizvod poliuretanskog elastomera, naznačen time, da ima najmanje dva od sljedećih svojstava: vrijednost Texus Flex-a na 30% od više od 10.000 ciklusa prema ASTM postupku D-3629-99; minimalno tan 6 na 30-160*C€ od oko 0,010 do 0,025; svojstvo jačine trganja od oko 26.3 do 78.8 N/mm u skladu s ASTM postupkom D-1938; i
Fig. 1 shows an assembly 1 of a drink dispenser 2 and a container 3 containing carbonated drink. 
Slika 1 prikazuje sklop 1 raspršivača pića 2 te spremnik 3 koji sadrži gazirano piće.
each waterproof tubular panel comprising at least an opening for injecting cementitious mixture for ballasting and frictionally anchoring each waterproof tubular panel to the bottom or the side banks of the canal or water basin; 
svaka ploča (14; 14A) sadržava barem jedan otvor za ubrizgavanje cementne smjese (30) za balastiranje i frikcijsko sidrenje svake ploče (14; 14A) na dno ili bočne strane kanala ili vodenog bazena.
Device according to claim 2, characterised in that the top rotation axis (A) is vertical. 
Uređaj sukladno zahtjevu 2, naznačen time što je gornja rotacijska os (A) vertikalna.
allowing the mouse to develop an immune response to the antigen of interest; and, identifying a clonally selected lymphocyte of the mouse that expresses an antibody that specifically binds the antigen of interest, and obtaining from the lymphocyte or the antibody a nucleotide sequence that encodes a human heavy chain variable region from the antibody that specifically binds the antigen of interest. 
(c) miš sadržava B-stanicu koja eksprimira protutijelo koje se specifično veže na antigen od interesa, pri čemu protutijelo sadržava navedeni zajednički laki lanac 1 teški lanac imunoglobulina dobivene preuređenjem genskih odsječaka varijabilne regije teškog lanca o (Vag) humanog imunoglobulina odabranih iz skupine koja se sastoji od odsječaka gena Vr2-5, Vu3-23, Vr3-30, Vu4-59 i Vn5-51 1
In another embodiment of the method, the modification is in a protein coding region of the gene encoding the selectable marker protein. 
Metoda iz patentnog zahtjeva 1 pri čemu je modifikacija u području za kodiranje proteina u genu koji kodira protein marker kojeg je moguće odabrati.
providing a solution of N-benzoyl-staurosporine in a solvent; 
(a) pribavljanje otopine N-benzoil-staurosporina u otapalu;
<400> 50 A antibody or antigen binding fragment thereof that binds to human IL-23, comprising: a light chain variable domain, or antigen binding fragment thereof, comprising CDRL1, CDRL2 and CDRL3, wherein: 
Antitijelo ili antigen-vežući fragment istog koji se veže za humani IL-23, naznačeno time, što sadrži: a) varijabilnu domenu lakog lanca, ili antigen-vežući fragment istog, koja sadrži CDRLI, CDRL2 i CDRL3, pri čemu:
n independently represents an integer equal to 2, 3 or 4; 
n neovisno predstavlja cijeli broj jednak 2, 3 ili 4;
P3563) to IL of double distilled H2O) using a plate washer then 200 ul Blocking Solution (5% Marvel dried skimmed milk (Nestle) in PBS/Tween 20) was added and incubated for 10 minutes. 
P3563) u 1 L destilirane vode), nakon čega se doda 200 pl otopine za blokiranje (5%-tno Marvel suho obrano mlijeko (Nestle) u PBS / Tween 20) i stavi na inkubaciju 10 minuta.
The assembly as recited in claim 9 wherein said mold chamber is structured to impart a predetermined configuration to the cooked food product produced during the cooking procedure. 
Sklop na način opisan u Zahtjevu 1 pri čemu je navedena komora kalupa strukturirana na način da pruža prethodno određenu konfiguraciju kuhanog prehrambenog proizvoda proizvedenog tijekom postupka kuhanja.
The antibody, immunoconjugate, pharmaceutical composition, bispecific or multispecific molecule or expression vector for the use according to claim 22, wherein the disease is B cell chronic lymphocytic leukemia. 
Protutijelo, imunokonjugat, farmaceutski pripravak, bispecifična ili multispecifična molekula za uporabu u skladu s patentnim zahtjevom 17, naznačeno time da je bolest kronična limfocitna leukemija B stanica.
Drying was completed using anhydrous magnesium sulphate and, after filtration, the solvent was removed at reduced pressure (shielded from the light, bath temperature <20 °C) to afford a pale yellow solid. 
Sušenje se završi uporabom anhidridnog magnezij sulfata i nakon filtriranja otapalo se ukloni uz smanjeni tlak (uz zaštitu od svjetla, temperatura kupelji <20*%C) da bi se dobila blijedo žuta krutina.
A pharmaceutical composition according to claim 20, wherein said additional active agent is selected from IGF-1, IGF-2 or variants of IGF-1 or IGF-2, an anti-myostatin antibody, a myostatin propeptide, a myostatin decoy protein that binds ActRIIB but does not activate it, a beta 2 agonist, a Ghrelin agonist, a SARM, GH agonists/mimetics or follistatin. 
Farmaceutski sastav prema zahtjevu 20, naznačen time, da navedeno dodatno djelotvorno sredstvo je odabrano od sljedećih: IGF-1, IGF-2 ili varijante od IGF-1 ili IGF-2, protutijelo anti-miostatin, miostatin-propeptid, miostatin-decoy-protein koji veže ActRIIB, ali ga ne aktivira, beta 2-agonist, Ghrelin-agonist, SARM, GH-agonisti/mimetici i folistatin.
The matrix is preferably glassy and non-crystalline in character. 
Matriks je poželjno staklast 1 ne-kristalan po karakteru.
4 mg Soft Capsules The ingredients below were mixed by an ordinary method and filled in soft capsules. 
4 mg 2) Meke kapsule Sastojci, niže, pomiješani su uobičajenim postupkom, te napunjeni u meke kapsule.
increases T cell proliferation; enhances the production of IFN-Y; or 
(C) posreduje proliferaciju T stanica; ili
An aqueous paracetamol solution for perfusion according to any one of the previous claims, further comprising derivatives of saccharic acids or sulfates or furfurals. 
Vodena otopina paracetamola za perfuziju sukladno bilo kojem od prethodnih patentnih zahtjeva, naznačena time, da dalje sadrži derivate šećernih kiselina ili sulfate ili furfurale.
Although these drugs more or less reduce the inflammation appearing in the CNS (in the primary form of the disease), they do not affect the progression of the disease (Clegg, Health Technol. 
Premda ovi lijekovi više ili manje uspješno smanjuju upalne pojave u CNS (kod primarnog oblika bolesti), ne djeluju na napredovanje bolesti (Clegg, Health Technol.
A compound of any of the following formulae: wherein R1 is selected from the group consisting of OR2 and NR3R4, and R2, R3 and R4 are each independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, aryl, alkylaryl, arylalkyl, and heteroaryl groups, wherein: "alkyl" means an aliphatic hydrocarbon group that can be straight or branched and comprises 1 to 24 carbon atoms in the chain; "alkenyl" means an aliphatic hydrocarbon group with straight or branched carbon chain comprising one or more double bonds in the chain, which can be conjugated or unconjugated, particularly comprising 2 to 15 carbon atoms in the chain; 
HR P20100218 T1 gdje R, se bira iz skupine koju čine OR> i NR:R., gdje svakog od R2, Ra i Ra se neovisno bira iz skupine koju čine H, alkilne, alkenilne, alkinilne, alkoksi, cikloalkilne, arilne, alkilarilne, arilalkilne i heteroarilne skupine, gdje: "alkil" znači alifatska ugljikovodična skupina koja može biti nerazgranata ili razgranata i sadrži 1 do 24 atoma ugljika u lancu; "alkenil" znači alifatska ugljikovodična skupina s nerazgranatim ili razgranatim lancem ugljika comprising jedan ili više dvostrukih veza u lancu, koje mogu biti konjugirane ili nekonjugirane, a osobito sadrži 2 do 15 atoma ugljika u lancu;
A method for dehydrating an organic material, comprising the steps of: 
Metoda za dehidraciju organskog materijala, koja obuhvaća korake: HR P20191831 T1
Formulation according to claim 5, wherein the aqueous solution is a buffer solution. 
Formulacija u skladu s patentnim zahtjevom 5, naznačena time što vodena otopina je puferska otopina.
The liquefied gas treatment system may further include a forcible vaporizer configured to forcibly vaporize the LNG stored in the cargo tank and supply the forcibly vaporized LNG to the compressor. 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 1, naznačen time što dodatno sadrži prisilni isparivač, podešen za prisilno isparavanje LNG spremljenog u spremniku za teret i slanje prisilno isparenog LNG u kompresor.
The compound [49] can be obtained by reacting compound [48] in the same manner as in Production Method 4-1, Step 5. 
(6) prevođenju spoja formule [48] u spoj formule [49] HR P20121020 T1 o ni 2
The reaction was quenched by addition of MeOH (5 mL) and stirring for 2 hours. 
Reakcijsku smjesu ugasi se dodavanjem MeOH (5 ml), te miješa 2 sata.
A method which, according to claims 1 to 4, is characterized by the fact that the result for the prognosis and/or diagnosis is positive if the quantity of protein Serum amyloid P-component (SAP, SAMP, SwissProt No: P02473) or fragment of it's amino acid sequence or of the modified protein is different (higher or lower) than the quantity of a reference protein. 
Metoda koja je, prema zahtjevima 1 do 4, naznačena time što je rezultat za prognozu i/ili dijagnozu pozitivan ako je količina proteinskog seruma amiloidne komponente P (SAP, SAMP, SwissProt br. PO2743) ili modificiranog proteina viša od količine referentnog proteina.
The method of claim 1, further comprising a PDE inhibitor selected from the group consisting of a PDE5 inhibitor, a PDE7 inhibitor and a PDE8 inhibitor. 
Pripravak za primjenu u skladu sa zahtjevima 1 do 4, naznačen time što sadrži i dodatni inhibitor PDE, izabran iz grupe inhibitora PDE5, PDE7 i PDE$.
In an embodiment, the immunogenic composition of the invention comprises a Hib saccharide conjugated to a carrier protein selected from the group consisting of TT, DT, CRM197, fragment C of TT and protein D. 
Imunogeni pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što saharid Hib je konjugiran s proteinskim nosačem kojeg se bira iz skupine koju čine TT, DT, CRMI197, C fragment proteina TT, protein D, OMPC i pneumolizin.
performing a stud welding action for each welding opening, wherein the welding pin is inserted into the welding opening, subsequently pushed through the underlying acoustic isolation layer, and pressed onto the metal surface of the first metal plate, in such a way that a welding current flows through the welding pin and the first metal plate, thereby melting and joining together the metal (8) of the welding pin and the first metal plate by that welding current, which stud welding action is continued until the space (9) between the welding pin and the welding opening is filled with molten metal (10) of the welding pin and the first and/or second metal plate. 
- provođenju zavarivanja svornjaka za svaki otvor za zavarivanje, gdje se zatik za zavarivanje umetne u otvor za zavarivanje, zatim gurne kroz donji sloj zvučne izolacije, te pritisne na metalnu površinu prve metalne ploče, tako da struja zavarivanja prolazi kroz zatik za zavarivanje 1 prvu metalnu ploču, čime dolazi do taljenja i spajanja zajedno metala (8) zatika za zavarivanje i prve metalne ploče strujom zavarivanja, gdje se sa zavarivanjem svornjaka nastavi dok se prostor (9) između zatika za zavarivanje i otvor za zavarivanje ne ispuni rastaljenim metalom (10) zatika za zavarivanje 1 prve i/ili druge metalne ploča.
Z is a targeting moiety that preferably is an antibody; 
(I gdje Zje ciljna grupa koja je poželjno antitijelo;
Use of the formulation according to claim 7, characterised in that the surfaces of the threads of screws, bolts and screw or sealing caps are not pre-treated with a primer. 
Primjena formulacije prema patentnom zahtjevu 5, naznačena time, da površine navoja vijaka, svornjaka i vijčanih ili zaptivnih glava nisu prethodno obrađene temeljnom bojom.
The process of claim 7, wherein the solvent is an alcohol. The process of claim 8, wherein the alcohol is selected from the group consisting of methanol, ethanol and isopropanol. 
Postupak prema zahtjevu 3, naznačen time da je otapalo izabrano iz skupine koja sadrži vodu, izopropanol, metanol, etanol, te odgovarajuću smjesu bilo koja dva ili više od navedenih otapala.
The computer cluster system according to claim 2, wherein the resource manager assigning the at least one hardware booster to the at least one hardware computation node triggers at least one of a group of signals, said group of signals comprising: a remote procedure call, a parameter handover, and a data transmission. 
Način raspoređivanja računalnog klastera u skladu s jednim od prethodnih patentnih zahtjeva, naznačen time, da spomenuto dodjeljivanje barem jednog pojačivača (B) jednom od navedenih više računalnih čvorova (CN) pokreće barem jednu od skupina signala, pri čemu navedena skupina sadržava: poziv daljinskog postupka, primopredaju parametara, prijenos podataka.
The process according to claim 1, wherein the talc ore provided in step (a) includes impurities selected from the group consisting of iron sulphide, carbon, or any mixture thereof. 
pri čemu je talk osiguran u koraku (a) odabran iz skupine koja sadrži rude magnezijevog karbonata, rude derivata serpentina, silikatne rude, ili njihove smjese, poželjno iz Sotkama (Finska);
Rotarod test, immediately after the simplified Irwin test 
- Rotarod test, neposredno nakon pojednostavljenog Irwin testa
A tablet comprising crystalline apixaban particles and a pharmaceutically acceptable diluent or carrier, wherein the tablet is obtainable by a process of manufacturing apixaban tablets, comprising the steps of: 
Tableta koja sadrži do 5 mg apiksabana i farmaceutski prihvatljivo otapalo ili nosač, gdje je tabletu moguće dobiti pomoću procesa koji obuhvaća korake:
A soft chewable veterinary composition according to claim 1 which is selected from the group consisting of: Ingredients Function 
Tableta prema bilo kojem od zahtjeva 8 do 9, naznačena time, da je njezin sastav odabran od formulacija A, B, C, D i E:
R<1> is hydrogen, halogen, C1-3 alkyl or C1-3 alkoxy, wherein said alkyl or alkoxy is unsubstituted or substituted with one or more halogen atoms; 
R! je vodik, halogen, C;3 alkil ili C,3 alkoksi, pri čemu je navedeni alkil ili alkoksi nesupstituiran ili supstituiran s jednim ili više atoma halogena;
and R21, taken together with the nitrogen atom to which they are attached, form an unsubstituted or substituted 5-6 membered heterocyclyl ring containing 1-2 heteroatoms selected from the group consisting of N and O; 
Ri R", uzeti zajedno sa atomom dušika za koji su vezani, formiraju nesupstituirani ili supstituirani 5-6 člani heterociklični prsten koji sadrži 1-2 heteroatoma izabrana iz grupe koja se sastoji od N i O;
A formulation according to claim 4, wherein the external coating is a mixture of methyl methacrylate and methacrylic acid, and methacrylic acid and ethyl acrylate copolymer, in a ratio comprised between 99:1 and 80:20. 
Formulacija u skladu s patentnim zahtjevom 4, pri čemu je vanjski omotač smjesa metil metakrilata 1 metakrilne kiseline, i kopolimera metakrilne kiseline i etil akrilata, u omjeru sadržanom između 99:1 1 80:20.
An LED module of claim 9, wherein said module circuit includes an amplifying circuit, wherein the gain of said amplifying circuit is a function of the sensed temperature of the LED. 
LED modul iz patentnog zahtjeva 24, naznačen time, da navedeni sklop modula sadržava pojačivački sklop, pri čemu je pojačanje navedenog pojačivačkog sklopa funkcija odčitane temperature LED diode.
Commercially available tetrabenazine is a racemic mixture of the RR and SS isomers and it would appear that the RR and SS isomers (hereinafter referred to individually or collectively as trans -tetrabenazine because the hydrogen atoms at the 3 and 11b positions have a trans relative orientation) are the most thermodynamically stable isomers. 
Komercijalno raspoloživ tetrabenazin je racemična smjesa RR 1 SS izomera i pokazati će se da su RR i SS izomeri (kasnije označeni pojedinačno ili skupno kao trans-tetrabenazini stoga što vodikovi atomi u položajima 3 i 11b imaju trans-relativnu orijentaciju) termodinamički najstabilniji izomeri. HR P20080677 T3
The starting mixture should comprise min. 70 % (mass/mass) of the organic component, most suitably about 80 % (mass/mass) and 0.2 to 0.5 % (mass/mass) of the biostimulants, calculated on the dry substance. 
Polazna smjesa treba sadržavati najmanje 70% (masa/masa), najprikladnije otprilike 80% (masa/masa) organske komponente i 0,2 do 0,5% (masa/masa) biostimulatora, računato na suhu tvar.
The process of claim 11 further comprising reacting compound (VII) with n-pentylmagnesium chloride; in the absence of a lithium halide; followed by the addition of carbon dioxide gas; in THF; at a temperature of about 0° C.; to yield the corresponding carboxylic acid compound (1c). 
Postupak prema zahtjevu 11, koji dalje obuhvaća reakciju spoja (VII) sa n-pentilmagnezij kloridom; u odsustvu litij halogenida; praćeno dodavanjem plina ugljikovog dioksida; u THF; na temperaturi od oko 0 °C; da bi se dobio odgovarajući spoj karboksilne kiseline (1c).
delivering the first reheated steam to the steam turbine generator (132). The method of claim 1 further comprising: recirculating a second portion of the output of the steam turbine generator for reheating in the coupled heat recovery steam generator to generate a second reheated steam (128); 
Postupak sukladno zahtjevu 1, koji dalje sadrži: recirkulaciju drugog dijela izlaza parne turbine-generatora radi ponovnog zagrijavanja u priključenom generatoru pare s rekuperacijom topline da bi se generirala druga ponovo zagrijana para (128); 1 odvođenje druge ponovo zagrijane pare do parne turbine-generatora (132).
The effect of the combination was significantly stronger than that of tolperisone administered alone (p=0.026; Mann-Whitney U test). 
Učinak kombinacije bio je značajno jači od učinka tolperisona datog samog (p = 0,026; Mann-Whitney-ev U test).